Pancreatic cancers: New drug doubles survival rate as France rolls out prevention program
Le Monde
—
In cases of metastatic pancreatic tumors, daraxonrasib has been shown to drastically increase survival rates, according to an international trial presented at the American Society of Clinical Oncology congress on Sunday.
In France, a personalized screening and prevention program, launched by the Gustave-Roussy Institute has been extended to eight additional centers.
Pancreatic Cancer Pill Doubles Survival
- Revolution Medicines reports Phase 3 win in pancreatic cancer Seeking Alpha —
- Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. ‘I actually started crying’ Fortune —
- New drug nearly doubles survival rates in some pancreatic cancer patients, study says CBS News —
- New drug offers ‘large step forward’ to treat advanced pancreatic cancer al.com —
- Why this new pill for a deadly cancer has doctors excited The i Paper —